ERBB2 and breast cancer: Both miRNAs play crucial roles in BC, which are as follows: dysregulation of miR-23b-5p is associated with trastuzumab resistance in HER2+ BC cells [75], while miR-155-5p has been implicated, e.g., as a predictive and prognostic biomarker for early BC recurrence and therapy resistance [76,77].